At @ weeks , there were significant treatment benefits in two independent populations at the @ mg/day dose : in moderate subjects on the ADAS-cog scale ( treatment effect : -@ units , corrected p = @ ) and two other clinical scales ; in mild subjects on the more sensitive regional cerebral blood flow measure ( treatment effect : @ % , corrected p < @ ) .